Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Annovis BioFRA:07X -6.29%39 PB Ratio is 16.00 as of Jul. 15, 2026. GuruFocus rates FRA:07X with a GF Score™ of 39/100. The stock has 1 warning sign investors should review. Among 1,228 Biotechnology companies, Annovis Bio ranks worse than 91.45% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-15), Annovis Bio's share price is €1.52. Annovis Bio's Book Value per Share for the quarter that ended in Mar. 2026 was €0.10. Hence, Annovis Bio's PB Ratio of today is 16.00.
The historical rank and industry rank for Annovis Bio's PB Ratio or its related term are showing as below:
FRA:07X'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 15.55
Current: 15.55
During the past 9 years, Annovis Bio's highest PB Ratio was 15.55. The lowest was 0.00. And the median was 0.00.
FRA:07X's PB Ratio is ranked worse than 91.45% of 1228
companies
in the Biotechnology industry
Industry Median: 2.895
vs FRA:07X: 15.55
During the past 12 months, Annovis Bio's average Book Value Per Share Growth Rate was -5.80% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -43.70% per year.
During the past 9 years, the highest 3-Year average Book Value Per Share Growth Rate of Annovis Bio was -43.70% per year. The lowest was -50.70% per year. And the median was -47.20% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Annovis Bio PB Ratio Related Terms
Annovis Bio PB Ratio Historical Data
* Premium members only.
The historical data trend for Annovis Bio's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Annovis Bio's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Annovis Bio PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Annovis Bio's PB Ratio distribution charts can be found below:
* The bar in red indicates where Annovis Bio's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Annovis Bio's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Annovis Bio (FRA:07X) has a PB Ratio of 16.00 as of Jul. 15, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Annovis Bio and its competitors. According to the industry distribution chart, Annovis Bio ranks #1123 out of 1228 companies in the Biotechnology industry, placing it in the top 91.4%.
Is Annovis Bio's PB Ratio too high?
Annovis Bio's current PB Ratio is 16.00. The Biotechnology industry median PB Ratio is 2.90. Annovis Bio's value of 16.00 is 452.7% above this industry median. Based on the distribution chart, Annovis Bio ranks #1123 out of 1228 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Annovis Bio has a GF Score™ of 39/100, reflecting its overall financial health beyond just this single metric.
How does Annovis Bio's PB Ratio compare to HYFT and EXOZ?
According to the Biotechnology industry distribution chart, Annovis Bio ranks #1123 out of 1228 companies for PB Ratio. This places Annovis Bio in the lower half of its industry. The industry median PB Ratio is 2.90. Annovis Bio's value of 16.00 is 452.7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.90, based on 1,228 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Annovis Bio's current PB Ratio of 16.00 is 452.7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Annovis Bio and its competitors. For the Biotechnology industry, the median PB Ratio is 2.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Annovis Bio's current PB Ratio is 16.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Annovis Bio stock overvalued right now?
Annovis Bio (FRA:07X) has a current PB Ratio of 16.00. The current PB Ratio is 16.00 and 452.7% above the Biotechnology industry median of 2.90. Annovis Bio's overall GF Score™ is 39/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Annovis Bio (FRA:07X), the current PB Ratio is 16.00 as of Jul. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.
39GF Score
Get the complete analysis for FRA:07X
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:07X has been successfully added to your 
